Cancer is a condition characterised by the uncontrolled growth and spread of abnormal cells, causing their massive aggregation producing either tumours or dispersal in the vascular system such as blood and lymph. Owing to a deviation from normal genetic makeup, cancer cells acquire immortality and a capability to evade apoptosis, non-responsiveness to anti-growth signals, self-sufficiency in growth factors, the ability to metastasise and to form new blood vessels that can supply nutrition and oxygen to the growing tissues. The transformation of normal to cancer cell occurs through accumulation of a series of genetic alterations or mutations, especially of oncogenes.
Carcinogenesis
There are many aetiological factors leading to cancer through a multistep process called carcinogenesis, which involves initiation, promotion, progression and malignant conversion. Mutation in a single cell initiates clonal expansion to form a premalignant lesion. These initiated cells will have resistance to cytotoxicity, defects in maturation, escape from senescence and have altered dependence on growth factors and hormones. Tumour promotion involves activation of cell surface receptors, activation/inhibition of cytosolic enzymes and nuclear transcription factors, stimulation of proliferation and inhibition of apoptotic cell death. Progression is accelerated by additional exposure to genotoxic agents and it is due to genetic instability and nonrandom sequential chromosomal aberrations. Malignant conversion involves multifocal change in premalignant lesions. There will be up-regulation of transcriptional activity and expression of modified cell surface molecules, gene amplification, alterations in cell-cycle regulatory genes, secreted proteases and methylation of DNA. All these changes facilitate migration and invasion.
Inhibition of carcinogenesis
As the progression of carcinogenesis is through a multistep pathway, there are many possible intervention sites inhibiting this progression. The procarcinogen can be detoxified and eliminated from the system. The conversion of procarcinogen to ultimate carcinogen is through multiple mechanisms including metabolic activation by enzymes. These mechanisms can be inhibited by blocking those enzymes involved in the activation step and several natural compounds of plant origin are reported as blocking agents in the chemoprevention of cancer, including flavonoids, ellagic acid and sulforaphane. These either block the conversion of carcinogen to ultimate carcinogen, or prevent the action of active metabolites on the normal cell. They may also alter carcinogen metabolism, enhance carcinogen detoxification, scavenge electrophiles and reactive oxygen species or enhance DNA repair.
The conversion of normal cells from preneoplastic cells to neoplastic cells takes several years, either by a second exposure to the carcinogen or promoting agent and accumulation of genetic variations. These steps can be inhibited by compounds such as curcumin, resveratrol, carotenoids, retinoids and genistein, which inhibit the malignant transformation of initiated cells by scavenging reactive oxygen species, altering gene expression, decreasing inflammation, suppressing proliferation, inducing differentiation, encouraging apoptosis, enhancing immunity or inhibiting angiogenesis and metastasis. Several chemopreventive phytochemicals have been shown to interfere with the cell-cycle regulatory pathways, qualifying them as potential therapeutic agents. Some are powerful inhibitors of growth factor receptors, including epidermal growth factor receptor (EGFR), and a variety of flavonoids are inhibitory, e.g. apigenin, luteolin, quercetin, catechin, epigallocatechin gallate, hesperitin, anthocyanins, genistein, with potential use in preventive anticancer treatment. Some phytochemicals undergoing clinical trials in the inhibition of carcinogenesis are given in Table: Selected ongoing Phase 1 and II cancer prevention trials sponsored by the US National Cancer Institute.
| Table: Selected ongoing Phase 1 and II cancer prevention trials sponsored by the US National Cancer Institute | |
| Target organ | Agent |
| Phase 1 trials | |
| Breast | Soy isoflavones |
| Colon | Curcumin |
| Prostate | Lycopene (3 trials); Soy isoflavones |
| Skin | Epigallocatechin gallate |
| Phase II trials | |
| Anogenital warts, human papillomavirus, HIV | Indole-3-carbinol |
| Cervix | 9-cis-Retinoic acid |
| Prostate | Soy (dietary); soy isoflavones |
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the most common primary malignant tumour of the liver and is the fifth most common cancer in the world, ranking fourth in annual mortality rates. An estimated 564 000 new cases of HCC are diagnosed each year, with the highest incidence in eastern and southeastern Asia, some of the western Pacific islands and sub-Saharan Africa. Men are affected four to eight times more often than women and the incidence generally increases with increasing age, although there is a definite shift towards a younger age distribution in black African and ethnic Chinese populations.
Aetiological factors
There are some well-documented aetiological associations of HCC. The aetiological association between hepatitis-B virus (HBV) and HCC is well established. Chronic HBV infection is the leading risk factor and it has been estimated that 53% of cases worldwide are related to HBV. Malignant transformation occurs after a long period of chronic liver disease, frequently associated with cirrhosis. Chronic inflammation of the liver, continuous cell death and consequent cell proliferation might increase the occurrence of genetic alterations and risk of cancer. The long-term expression of regulator gene product of the X-gene and large envelope proteins (LHBs) are thought to play a major role in tumorigenesis. This viral oncoprotein behaves as a transcriptional transactivator, which activates oncogenes, cytokines and growth factors. A direct role of the virus through integration of viral DNA directly to host genome has also been hypothesised that may enhance chromosomal instability, large inverted duplications, deletions, amplifications or chromosomal translocations which lead to the activation of oncogenic pathways.
Chronic HCV (hepatitis C virus) infection is also associated with HCC. The HCC incidence rate in patients with HCV-related cirrhosis is about 3.7%.
Chemical carcinogens which are linked to HCC include nitrites, hydrocarbons, solvents, organochlorine pesticides, primary metals and polychlorinated biphenyls. Of all the chemicals linked to HCC, ethanol is the most important one that leads to HCC. Overconsumption of alcohol is one of the leading causes of liver cirrhosis which makes the patient more susceptible to HBV and HCV infection.
Aflatoxins produced by the fungi, Aspergillus flavus and A. parasiticus have also been linked to HCC. These fungal species grow on grains, peanuts and other food products and are the most common cause of food spoilage. These fungi also produce aflatoxins, aflatoxin Bl being the most hepatotoxic and chronic exposure to these mycotoxins will lead to HCC.
Some congenital conditions also lead to development of HCC. Genetic diseases such as haemochromatosis, Wilson’s disease, hereditary tyrosinaemia, type I glycogen storage disease and porphyria, have all been linked to a high incidence of HCC.
Symptoms and markers
The symptoms related to the early stages of HCC are poor. When HCC presents with clinical symptoms, the tumour is usually advanced and there are few therapeutic options. The current effective treatments available are only applicable in a relatively small proportion of early stage cases.
Serum a-fetoprotein is a useful tumour marker for the detection and monitoring of HCC development, but gives false-negatives in about 40% of patients. Serum Ύ-glutamyl transpeptidase (GGT) is frequently overexpressed in cancer cells. GGT activity is a sensitive marker of hepatobiliary disorders, exhibiting tissue-specific expressions under various physiological and pathological conditions. Other enzymes that are increased in the blood during HCC include alkaline phosphatase, alanine trans-aminase and aspartate transaminase, but they are non-specific.
The overexpression of transforming growth factor (TGF)-β1 and TGF-β1 messenger RNA is seen in most patients with HCC. The level of insulinlike growth factor (IGF)-II and IGF-II mRNA is also overexpressed in HCC. The analysis of telomerase activity in combination with α-fetoprotein increases the accuracy of HCC diagnosis to about 93%.
Even though tumours present limitations for cytogenetic analysis, there are some reports of cytogenetic analysis of HCC. They include chromosome 1p abnormalities and 8q amplification. Molecular studies have demonstrated frequent loss of heterozygosity on 1p, 4q, 8p, 11p, 13q, 16q and 17p and amplification of 8q areas in HCC.
Models
Rodents are usually studied as models of hepatic carcinogenesis. Many chemicals induce liver cancer in rodents since their livers are very sensitive to chemical carcinogens. Thus, a single experimental protocol can be used to understand the mechanisms of a number of carcinogens. The low cost of rodents and their potential for genetic studies and manipulation are also attributes. Apart from this, a fairly extensive understanding of liver biology has made rodent HCC a popular model. Other models used for HCC study include hamsters and other non-primates.
The chemicals used to study the initiation of HCC include nitrosamines, aromatic amines, vinyl chloride, polycyclic aromatic hydrocarbons, hetero-cyclic amines, aflatoxin and tamoxifen. The promoters which are used after initiation include phenobarbital, dioxin and polychlorinated biphenyl. The mechanism of action of these chemical carcinogens is combination with DNA to form adducts, either by direct binding to DNA, or after enzymatic activation in the liver to produce the carcinogen. Some agents that produce hepatic carcinogenesis are discussed below.
Polycyclic aromatic hydrocarbons
Polycyclic aromatic hydrocarbons require metabolic activation to elicit their detrimental effect, e.g. benzo(a)pyrene is enzymatically activated to the 7,8-dihydrodiol, which induces both somatic mutations in crucial genes through DNA binding and subsequent outgrowth of irreversibly transformed cells.
Aryl amines/amides
In rodents these compounds induce tumours in the liver, e.g. acetamido-fluorine undergoes N-hydroxylation in liver cells. Additional tumour-promoting activities of acetamido-fluorine include the triggering of adaptive responses in mitochondria permeability transition pores and Bcl-2 production levels that increase resistance to apoptosis.
Alcohol
The mechanism of ethanol-induced cancer is closely related to its metabolism. Acetaldehyde, the end-product of ethanol metabolism, is the causative agent of cancer in chronic conditions. Oxidative stress and cirrhosis are important factors in ethanol-induced HCC.
Nitrosamines
These are the most widely used chemical carcinogen for animal experiments. N‘-nitrosodiethylamine (NDEA) is metabolised in the liver and its ethyl radical product is responsible for induction of HCC. This radical attacks the DNA and produces genetic changes which result in carcinogenesis. It also produces the conversion of certain proto-oncogenes to oncogenes.
Azo dyes
Para-dimethylaminoazobenzene (p-DAB) is metabolised to monoaminoazobenzene by N-demethylation and subsequently to aminoazobenzene or to N-hydroxy-N-methyl-4-aminoazobenzene. Covalent bindings of these metabolites with DNA are major carcinogenic factors.
Aflatoxins
Aflatoxins are highly mutagenic and are metabolised by cytochrome p450 to their epoxides, which results in formation of DNA adducts with the guanine N7, thus causing carcinogenicity.
Treatment
If detected early, suitable curative treatments include surgical resection, liver transplantation and percutaneous ablation. In patients with advanced stage of HCC, transarterial chemoembolisation has been proved to improve survival in selected candidates. Other therapeutic modalities such as intra-arterial chemotherapy and internal radiation offer promising results but have not been shown to improve survival. As HCC is usually chemoresistant, cytotoxic drugs are poorly tolerated in cirrhotic patients so many of the known anticancer agents, e.g. tamoxifen, octreotide, interferon, fail to produce any benefit in HCC patients. Promising results have been obtained with agents targeting receptor tyrosine kinase pathways. Since HCC is dependent on angiogenesis, molecules targeting the angiogenesis are currently under investigation. BAY 43-9006, which inhibits multiple pathways, mainly Raf kinase and VEGF, has been undergoing Phase II and III trials and has shown a partial response in a patient with advanced HCC.
The presence of unlimited chemical molecules, with diverse mechanisms, present in herbal drugs makes them interesting starting points in the search for newer drugs for cancer treatment.
Natural templates for treatment
The plant kingdom produces many potent pharmacologically active components, several of which have provided promising results to combat various diseases. Possible uses of herbal drugs in cancer are illustrated in Figure: Potential uses of herbal drugs in cancer treatment.
The chemical basis of some anticancer plants has been elucidated and some are now used clinically. Plant extracts and their constituents which show significant activity against hepatic cancer are described in more detail below.
Curcuma longa (turmeric)
The rhizome of C. longa (Zingiberaceae) is described as an anti-inflammatory agent in Ayurveda and is widely used in foods and as a medicine thoughout India and other Asian countries as a treatment for liver disorders, including cancer. The most-studied ingredient in the rhizome is curcumin but several related compounds are present such as demethoxy-curcumin and bidemethoxycurcumin.
Curcumin treatment has been reported to reduce tumour incidence and inhibit the liver inflammation and hyperplasia in N-nitrosodiethylamine-induced liver-cancer-bearing animals. The chemopreventive effect of turmeric and curcumin against diethylnitrosamine-induced and phenobarbital-promoted hepatocarcinogenesis has been reported. Curcumin also suppressed diethylnitrosamine-induced development of altered hepatic foci in rat liver. The number of Ύ-GT positive foci induced by aflatoxin Bl was found to be reduced by curcumin treatment. Curcumin significantly protected the liver from oxidative stress-induced damage during chemically induced hepatocarcinogenesis in rats.
In a patient study, Curcuma aromatic oil showed a positive effect in treating primary liver cancer with longer survival time and myelosuppression. Curcumin treatment reduced the tumour incidence by inhibiting angiogenesis through down-regulating cyclo-oxygenase 2 and vascular endothelial growth factor in HepG2 cells. It was reported that curcumin induces mitochondrial and nuclear DNA damage, thereby inducing apoptosis through caspase 3 and 9 activation. Curcumin also suppressed intrahepatic metastasis mediated by the inhibition of MMP-9 and through alteration of cytoskeletal organisation. In-vitro studies showed that the production of p21(ras) was inhibited by curcumin. It also inhibited transcription factor NF-kB and IAP gene expression. External curcumin application has been tried as a palliative therapy for cancerous skin lesions. Clinical trials (Phase I and II) of curcumin are being carried out in several hospitals to find out its therapeutic role against colon cancer, pancreatic cancer, hepatocellular cancinoma and multiple myeloma. Curcumin was found to be non-toxic at doses up to 12 g/day in patients.
Silybum marianum (milk thistle)
The active ingredients present in Silybum marianum (Compositae) are the flavonolignans silymarin and silybinin. Silymarin has been proposed as a promising chemotherapeutic adjuvant for the treatment of liver cancer. N‘-nitrosodiethylamine-induced hepatocellular carcinoma was found to be inhibited by silymarin by modulating antioxidant defence status in rats. Silybin was found to inhibit the growth of Hep3B and HepG2 cells by G1 arrest. The apoptosis-inducing property of silybin has been shown to be through decreasing cyclin D1, cyclin D3, cyclin E and cyclin dependent kinases 2 and 4. Silymarin can suppress the proliferation of a variety of tumour cells through cell cycle arrest at the G1/S-phase, induction of cyclin-dependent kinase inhibitors (such as p15, p21 and p27), down-regulation of anti-apoptotic gene products (e.g. Bcl-2 and Bcl-xL), inhibition of cell-survival kinases (AKT, PKC and MAPK) and inhibition of inflammatory transcription factors (e.g. NF-kβ). Silymarin can also down-regulate gene products involved in the proliferation of tumour cells (cyclin D1, EGFR, COX-2, TGF-beta, IGF-IR), invasion (MMP-9), angiogenesis (VEGF) and metastasis (adhesion molecules). The anti-inflammatory effects of silymarin are mediated through suppression of NF- kβ -regulated gene products, including COX-2, LOX, inducible iNOS, TNF and IL-1. Treatment of patients with hepatitis B or C infection with silymarin seemed to be effective, although no effect in decreasing viral load was found.
Camellia sinensis (tea)
Constituents of Camellia sinensis (Theaceae) include flavonols, e.g. myricetin, kaempferol and quercetin; as well as caffeine and proanthocyanidins such as epigallocatechin gallate. Green tea was observed to have protective effect on liver cancer in population-based studies.
In multidose NDEA-induced HCC followed by carbon tetrachloride injection and partial heptoectomy studies, it was found that treatment with tea polyphenols and pigment showed significant reduction in number and area of GST-positive foci, which is a proliferative indicator of precancerous liver lesions by immunohistochemistry.
Green tea was reported to exert antiproliferative activity towards hepatoma cells. Green tea was also reported to possess chemopreventive activity against nitrosamine-initiated hepatocellular carcinoma. It was found that the production of p21(WAF1/CIP1) was significantly induced and that of cyclin Dl and cyclin-dependent kinase 4 were inhibited in tea-treated animals. Tea catechins, black tea extract and oolong tea extract are also reported to inhibit hepatocellular carcinoma.
Allium sativum (garlic)
The bulbs of Allium sativum (Alliaceae) have been described as useful against inflammation and tumours in Ayurveda. The anticarcinogenic activity of whole garlic, as well as its isolated ingredients, against NDEA-induced hepatocellular carcinoma in animals is well documented. Aged garlic extract inhibited the development of putative lesions in rat hepatocarcino-genesis involving a slowing in the proliferation rate of liver cells after partial hepatoectomy. Garlic powder inhibited the formation of preneoplastic foci during hepatocarcinogenesis initiated by diethylnitrosamine through suppression of CYP2E1. The organosulphur compounds isolated from garlic are highly active against liver cancer. There was a decrease in the number of preneoplastic, GST-positive foci of the liver and also a down-regulation of IGF-I and iNOS mRNA expression in the liver of organosulphur-treated animals which were induced with 2-amino-3,8-dimethylimidazo [4-5-f] quinoxaline. The protective effect of diallylsulphide isolated from garlic against HCC was reported by Singh et al. (2004). S-allylcysteine, an organosulphur compound, showed inhibition of tumour incidence and lipid peroxidation in NDEA-induced hepatic cancer animals with simultaneous elevation in antioxidants.
Benzo(a)pyrene-induced cancer was found to be inhibited by garlic constituents such as diallylsulphide (DAS), diallyldisulphide (DADS) and diallyltrisulphide (DATS). Diallylsulphide prevented DNA adducts induced by the carcinogen, thereby preventing the initiation of oestrogen-induced cancer. Allylthiopyridazine derivatives induced apoptosis in Sk-Hep-1 cells through a caspase-3-dependent mechanism and this also contributes to their chemopreventive function. The antiproliferative property of aqueous garlic extract was studied in HepG2 cells and it was found that these compounds induced a p53/p21-dependent cell cycle arrest in G2/M phase and apoptosis through activation of c-Jun-NH (2) terminal kinase (JNK)/c-Jun phosphorylative cascade. DAS, DADS and DATS also caused G2/M phase arrest in human liver tumour cells.
Emblica officinalis Gaertn. (emblica)
The extract of fruits of Emblica officinalis (Euphorbiaceae) was reported to give chemoprotection against chemically induced carcinogenesis. The fruits are rich in polyphenolic compounds such as gallic acid, tannic acid, emblicanin A and B and ellagitannins. Polyphenolic compounds, such as epigallo-catechin gallate, found in tea are also present in Emblica officinalis. Because of the presence of these compounds, emblica extract has been shown to possess significant antioxidant activity and is also antimutagenic, inhibiting DNA adducts produced by benzo(a)pyrene. The polyphenolic fraction of Emblica officinalis was found to modulate NDEA-induced hepatic cancer in rats. In-vitro experiments showed that it inhibited DNA topoisomerase I in Saccharomyces cerevisiae mutant cell culture and also inhibited the activity of cdc25 tyrosine phosphatase.
Phyllanthus amarus
The fresh root of Phyllanthus amarus (Euphorbiaceae) is said to be an excellent remedy for jaundice. The components present in Phyllanthus amarus are lignans, e.g. phyllanthin; tannins, e.g. phyllanthusiin D3, amariin and amarulone; alkaloids, e.g. entnorsecurinine, diarylbutanes; and neolignans, e.g. phyllnirurin. A variety of hydrolysable tannins purified from Phyllanthus amarus were reported to be potent inhibitors of rat liver cyclic AMP-dependent protein kinase catalytic subunit. Phyllanthus amarus extract was reported to significantly inhibit NDEA-induced hepatocar-cinogenesis in rats in a dose-dependent manner. In another study the lifespan of rats bearing NDEA-induced hepatocellular carcinoma was found to be significantly increased by the treatment with Phyllanthus amarus, from 33 weeks to 52 weeks. Phyllanthus amarus extract has been shown to have antiviral activity against hepatitis B virus. In a patient study, it was found that approximately 60% of the carriers of HBV lost the virus within 1 month of Phyllanthus amarus treatment.
Picrorhiza kurroa (kutki)
The root/rhizomes of Picrorhiza kurroa (Scrophulariaceae) are used in Ayurveda against jaundice. The components present in the root include the glycosides picrorhizin and kutkin, and sterols. Picroliv, an iridoid glycoside mixture prepared from this plant, contains equal concentrations of picroside and kutkoside as well as vanillic acid and sterols. Amelioration of NDEA-induced hepatocellular carcinoma was seen in animals treated with Picrorhiza kurroa extract, and there was a significant reduction in the levels of drug-metabolising enzymes such as glutathione-S-transferase (GST) and aniline hydroxylase (AH). Liver morphology and histopathology also revealed the protective effect of the extract against chemical carcinogenesis. Picroliv was found to inhibit HCC and was also reported to possess protective effect against 1,2-dimethylhydrazine-induced HCC in animals. Picroliv significantly down-regulated transcription factor API and thereby decreased the level of c-fos mRNA as well as c-jun and c-fos proteins in liver tissue. This would indicate a base for their potential anti-HCC activity.
Semecarpus anacardium (marking nut)
The rind of the fruit of Semecarpus anacardium (Anacardiaceae) is used in Ayurvedic medicine against inflammatory diseases. The active ingredient is usually reckoned as anacardic acid. Semecarpus anacardium nut extract affords anti-cancer activity by enhancing both phase I and phase II enzymes and it has been proposed that the anticancer activity may be mediated through the induction of hepatic biotransformation enzymes. It was found to modulate the carcinogenic effect of aflatoxin by enhancing anti-oxidant capacity in the system.
Andrographis paniculata (creat)
The root of Andrographis paniculata (Acanthaceae) is used in both Ayurvedic and Chinese medicine. The component present is a diterpene lactone andrographolide. The roots also contain a variety of compounds including the sesquiterpene andrographolide. The effectiveness of Andrographis paniculata was found to be through modulating hepatic and extra-hepatic carcinogen-metabolising enzymes and antioxidant status. Andrographis paniculata extract and andrographolide stimulated CTL production through enhanced secretion of IL-2 and IFN-Ύ by T cells and thereby inhibited the tumour growth. The species has been reported to modulate the immune response through enhancing natural killer (NK) cell activity and antibody-dependent cell-mediated cytotoxicity and antibody-dependent complement mediated cytotoxicity in tumour-bearing animals.
Glycine max (soybean)
Glycine max (Papilionaceae) contains isoflavone glycosides genistein and diadzin as active principles but certain saponin constituents were also found to be biologically active. The administration of 30% soybean to the rat diet was found to have protective effect against hepatocarcinogenesis induced by DL-ethionone. There was a 92.7% increase in lifespan in rats with primary liver cancer when treated with doxorubicin encapsulated with soybean-derived sterylglycoside mixture when compared with free doxorubicin. Genistein was found to inhibit diethyl-nitrosamine-induced and phenobarbital-promoted HCC. Genistein has been reported to inhibit lung metastasis in animals. Genistein was found to inhibit cell proliferation and induced apoptosis through caspase-3 induction and caspase-2 activation. In another study apoptosis was induced by genistein in Hep 3B cells through initiating endoplasmic reticular stress relevant regulators including m-calpain, GADD 153, GRP 78 and caspase-12.
Panax ginseng (ginseng)
Panax ginseng (Araliaceae) root (white and red) is extensively used in traditional Chinese medicine against various diseases. Ginseng contains polysaccharides and saponins, those known as ginsenosides are commonly considered to be the active constituents. The incidence of liver tumour development was lower in animals treated with red ginseng extract, and the average number of tumours per mouse was significantly reduced in the treated group. White ginseng was also found to possess anticarcinogenic properties both in vitro and in vivo. In another study, red ginseng was found to possess both preventive as well as curative properties against diethylamine-induced hepatic cancers in rats.
Terminalia arjuna (arjuna bark)
Terminalia arjuna (Combretaceae) bark is extensively used against tumours in Ayurvedic medicine. Terminalia arjuna was reported to possess chemopreventive activity in NDEA-induced HCC-bearing animals. In another study, diethylnitrosamine-induced HCC was inhibited by Terminalia arjuna bark extract through modulating the antioxidant status in tumour-bearing animals. The ingredients of Terminalia arjuna bark include flavonoids, e.g. arjunone, arjunolone and luteolin; phenols, e.g. gallic acid and ellagic acid; and terpenoids, e.g. oleanolic acid. The antitumour potential of luteolin and triterpenoids has been reported, while phenolic ingredients have significant chemopreventive activity.
Other plants
Baubinia variegata and Baubinia racemosa were reported to ameliorate NDEA-induced HCC in rats through modulation of antioxidant enzymes. Chemopreventive potential of extracts from Tamarix gallica, Paullina cupana, Butea monosperma, Lygodium flexuosum, Indigofera aspalatboides, Apium graveolens, Solanum trilobatum, Ardisia compressa, Calotropis procera, Amaranthus gageticus, Astragalus membranaceus, Beta vulgaris, Cymbopogon citrates, Asteracantha longifolia, Triantbema portulacastrum etc. has been reported in hepatic cancer models in animals.
Conclusions
There is no really effective treatment for hepatocellular carcinoma and so it stands high in global cause of mortality. Chronic hepatitis and lifestyle-induced oxidative stress are the major factors associated with hepatic cancer. It is detected in the later stages in many patients, and the current treatment modalities fail to keep the disease under control. Plants and plant-derived compounds have been found to be effective against hepatic cancer in animal models and through a few clinical studies. The antiviral and free-radical scavenging activities of the plant-derived constituents in many cases have proven to be beneficial. Many of the compounds, e.g. curcumin, are in the process of being testing in clinical trials and are giving promising results, while explorations for newer compounds are still progressing.
